| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7767675 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US8461330 | NOVARTIS PHARM | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
Nov, 2027
(4 years from now) | |
| US8420645 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
Jun, 2031
(7 years from now) | |
| US10596178 | NOVARTIS PHARM | Tablet formulation of 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide |
Jul, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8901123 | NOVARTIS PHARM | Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-B][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same |
May, 2029
(5 years from now) | |
Tabrecta is owned by Novartis Pharm.
Tabrecta contains Capmatinib Hydrochloride.
Tabrecta has a total of 5 drug patents out of which 0 drug patents have expired.
Tabrecta was authorised for market use on 06 May, 2020.
Tabrecta is available in tablet;oral dosage forms.
Tabrecta can be used as use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation.
Drug patent challenges can be filed against Tabrecta from 2024-05-06.
The generics of Tabrecta are possible to be released after 22 July, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | May 6, 2025 |
| Orphan Drug Exclusivity (ODE) | May 6, 2027 |
Drugs and Companies using CAPMATINIB HYDROCHLORIDE ingredient
NCE-1 date: 2024-05-06
Market Authorisation Date: 06 May, 2020
Treatment: Use for the treatment of patients with metastatic non-small cell lung cancer (nsclc) with a mesenchymal-epithelial transition (met) exon 14 skipping mutation
Dosage: TABLET;ORAL
TABRECTA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic